Roberta Fruttero

List of Publications by Year in Descending Order

152 papers	3,723 citations	32 h-index	50 g-index
163 ext. papers	4,113 ext. citations	5.3 avg, IF	4.64 L-index

#	Paper	IF	Citations
152	Tuning NO release of organelle-targeted furoxan derivatives and their cytotoxicity against lung cancer cells. *Bioorganic Chemistry*, **2021**, 111, 104911	5.1	3
151	A generator of peroxynitrite activatable with red light. *Chemical Science*, **2021**, 12, 4740-4746	9.4	1
150	NO release regulated by doxorubicin as the green light-harvesting antenna. *Chemical Communications*, **2020**, 56, 6332-6335	5.8	2
149	DNA-Targeted NO Release Photoregulated by Green Light. *Chemistry - A European Journal*, **2020**, 26, 13627-13633	4.8	1
148	In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin. *European Journal of Pharmacology*, **2020**, 880, 173164	5.3	3
147	One molecule two goals: A selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells. *European Journal of Medicinal Chemistry*, **2020**, 208, 112843	6.8	4
146	Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. *Drug Resistance Updates*, **2020**, 50, 100682	23.2	72
145	MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118824	4.9	5
144	Molecular dynamics simulations reveal the determinants of cyclin-dependent kinase 2 inhibition by 5-nitrosopyrimidine derivatives. *Journal of Biomolecular Structure and Dynamics*, **2020**, 38, 4016-4024	3.6	
143	Fluorescent Nitric Oxide Photodonors Based on BODIPY and Rhodamine Antennae. *Chemistry - A European Journal*, **2019**, 25, 11080-11084	4.8	18
142	Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. *Cancer Letters*, **2019**, 456, 29-39	9.9	26
141	Combination of PDT and NOPDT with a Tailored BODIPY Derivative. *Antioxidants*, **2019**, 8,	7.1	5
140	Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells. *Journal of Medicinal Chemistry*, **2019**, 62, 974-986	8.3	13
139	A molecular hybrid producing simultaneously singlet oxygen and nitric oxide by single photon excitation with green light. *Bioorganic Chemistry*, **2019**, 85, 18-22	5.1	15
138	New tetrahydroisoquinoline-based P-glycoprotein modulators: decoration of the biphenyl core gives selective ligands. *MedChemComm*, **2018**, 9, 862-869	5	9
137	Tuning the Hydrophobicity of a Mitochondria-Targeted NO Photodonor. *ChemMedChem*, **2018**, 13, 1238-1245	3.7	5
136	New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro. *Molecules*, **2018**, 23,	4.8	9

135	Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors. *European Journal of Medicinal Chemistry*, **2018**, 144, 612-625	6.8	13
134	Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. *Journal of Controlled Release*, **2018**, 270, 37-52	11.7	47
133	A Molecular Hybrid for Mitochondria-Targeted NO Photodelivery. *ChemMedChem*, **2018**, 13, 87-96	3.7	10
132	Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation. *European Journal of Medicinal Chemistry*, **2018**, 154, 341-353	6.8	7
131	Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance. *ACS Medicinal Chemistry Letters*, **2017**, 8, 361-365	4.3	35
130	Furoxan Nitric Oxide Donors Disperse Pseudomonas aeruginosa Biofilms, Accelerate Growth, and Repress Pyoverdine Production. *ACS Chemical Biology*, **2017**, 12, 2097-2106	4.9	14
129	A Nonmetal-Containing Nitric Oxide Donor Activated with Single-Photon Green Light. *Chemistry - A European Journal*, **2017**, 23, 9026-9029	4.8	22
128	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity. *Journal of Medicinal Chemistry*, **2017**, 60, 8647-8660	8.3	29
127	-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension. *ACS Medicinal Chemistry Letters*, **2017**, 8, 1054-1059	4.3	3
126	Synthesis and Biological Evaluation of N(2) -Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors. *ChemMedChem*, **2016**, 11, 1705-8	3.7	5
125	Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4'-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein. *Journal of Medicinal Chemistry*, **2016**, 59, 6729-38	8.3	17
124	Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 967-75	3.4	21
123	In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition. *Pharmacological Research*, **2016**, 103, 132-43	10.2	9
122	Light-Tunable Generation of Singlet Oxygen and Nitric Oxide with a Bichromophoric Molecular Hybrid: a Bimodal Approach to Killing Cancer Cells. *ChemMedChem*, **2016**, 11, 1371-9	3.7	22
121	A Potent and Selective P-gp Modulator for Altering Multidrug Resistance Due to Pump Overexpression. *ChemMedChem*, **2016**, 11, 374-6	3.7	11
120	H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. *Journal of Medicinal Chemistry*, **2016**, 59, 4881-9	8.3	35
119	Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis. *European Journal of Medicinal Chemistry*, **2016**, 123, 523-531	6.8	48
118	NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria. *Journal of Medicinal Chemistry*, **2015**, 58, 7895-9	8.3	15

117	A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion. *Oxidative Medicine and Cellular Longevity*, **2015**, 2015, 804659	6.7	18
116	NO-donor thiacarbocyanines as multifunctional agents for Alzheimer's disease. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 4688-4698	3.4	16
115	A multi-photoresponsive molecular-hybrid for dual-modal photoinactivation of cancer cells. *RSC Advances*, **2014**, 4, 44827-44836	3.7	12
114	New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni. *European Journal of Medicinal Chemistry*, **2014**, 84, 135-45	6.8	43
113	On the self-condensation of aminoguanidine leading to 1,1,4,10,10-pentaamino-2,3,5,6,8,9-hexaazadeca-1,3,5,7,9-pentaene (structure elucidation through X-ray powder diffraction). *Tetrahedron*, **2014**, 70, 8056-8061	2.4	2
112	Furazan and furoxan sulfonamides are strong □carbonic anhydrase inhibitors and potential antiglaucoma agents. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 3913-21	3.4	25
111	Leishmanicidal activities of novel synthetic furoxan and benzofuroxan derivatives. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 4837-47	5.9	32
110	Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells. *Molecular Pharmaceutics*, **2014**, 11, 3068-79	5.6	27
109	Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 2107-16	3.4	12
108	Doxorubicin-antioxidant co-drugs. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5307-10	2.9	19
107	The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors. *Journal of Molecular Modeling*, **2013**, 19, 1099-107	2	18
106	6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: a new scaffold endowed with potent CDK2 inhibitory activity. *European Journal of Medicinal Chemistry*, **2013**, 68, 333-8	6.8	14
105	Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 715-9	2.9	28
104	Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. *Molecular Pharmaceutics*, **2013**, 10, 161-74	5.6	52
103	Water-soluble nitric-oxide-releasing acetylsalicylic acid (ASA) prodrugs. *ChemMedChem*, **2013**, 8, 1199-209	3.7	18
102	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor. *ACS Medicinal Chemistry Letters*, **2013**, 4, 994-9	4.3	36
101	A rapid screening for cytochrome P450 catalysis on new chemical entities: cytochrome P450 BM3 and 1,2,5-oxadiazole derivatives. *Journal of Biomolecular Screening*, **2013**, 18, 211-8		6
100	New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold. *European Journal of Medicinal Chemistry*, **2012**, 49, 102-9	6.8	25

99	Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 841-50	3.4	5
98	Synthesis and preliminary biological profile of new NO-donor tolbutamide analogues. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3810-5	2.9	18
97	Thymopentin down-regulates both activity and expression of iNOS in blood cells of Sjögren syndrome patients. *Nitric Oxide - Biology and Chemistry*, **2012**, 27, 143-9	5	8
96	Designing multitarget anti-inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors. *ChemMedChem*, **2012**, 7, 1647-60	3.7	22
95	Carnosine analogues containing NO-donor substructures: synthesis, physico-chemical characterization and preliminary pharmacological profile. *European Journal of Medicinal Chemistry*, **2012**, 54, 103-12	6.8	10
94	Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents. *Journal of Medicinal Chemistry*, **2011**, 54, 611-21	8.3	27
93	Searching for new NO-donor aspirin-like molecules: Furoxanylacyl derivatives of salicylic acid and related furazans. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 5852-60	3.4	25
92	New nitric oxide or hydrogen sulfide releasing aspirins. *Journal of Medicinal Chemistry*, **2011**, 54, 5478-84	8.3	28
91	1,2,5-Oxadiazole analogues of leflunomide and related compounds. *European Journal of Medicinal Chemistry*, **2011**, 46, 383-92	6.8	23
90	Amodiaquine analogues containing NO-donor substructures: synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria. *European Journal of Medicinal Chemistry*, **2011**, 46, 1757-67	6.8	26
89	Nitrooxyacyl derivatives of salicylic acid: aspirin-like molecules that covalently inactivate cyclooxygenase-1. *ChemMedChem*, **2011**, 6, 523-30	3.7	7
88	Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity. *ACS Medicinal Chemistry Letters*, **2011**, 2, 494-7	4.3	58
87	Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 3431-4	2.9	18
86	Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. *Journal of Experimental Medicine*, **2011**, 208, 1949-62	16.6	455
85	4-hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological characterization at ionotropic glutamate receptors of compounds related to glutamate and its homologues. *Journal of Medicinal Chemistry*, **2010**, 53, 4110-8	8.3	21
84	Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein. *Journal of Medicinal Chemistry*, **2010**, 53, 5467-75	8.3	49
83	Physicochemical profile and in vitro permeation behavior of a new class of non-steroidal anti-inflammatory drug candidates. *European Journal of Pharmaceutical Sciences*, **2010**, 40, 217-21	5.1	1
82	Multitarget drugs: synthesis and preliminary pharmacological characterization of zileuton analogues endowed with Dual 5-LO inhibitor and NO-dependent activities. *ChemMedChem*, **2010**, 5, 1444-9	3.7	1

81	Nitrooxymethyl-substituted analogues of rofecoxib: synthesis and pharmacological characterization. *Chemistry and Biodiversity*, **2010**, 7, 1173-82	2.5	15
80	Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). *Bioorganic and Medicinal Chemistry*, **2010**, 18, 2428-38	3.4	21
79	Unsymmetrically substituted furoxans. Part 19. Methyl and phenylfuroxansulfonic acids and related sulfonamides. *Journal of Heterocyclic Chemistry*, **2009**, 46, 866-872	1.9	10
78	Nitrooxymethyl-substituted analogues of celecoxib: synthesis and pharmacological characterization. *Chemistry and Biodiversity*, **2009**, 6, 369-79	2.5	14
77	A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity. *European Journal of Medicinal Chemistry*, **2009**, 44, 5071-9	6.8	27
76	Edaravone derivatives containing NO-donor functions. *Journal of Medicinal Chemistry*, **2009**, 52, 574-8	8.3	31
75	(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins. *Journal of Medicinal Chemistry*, **2009**, 52, 5058-68	8.3	30
74	Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile. *Journal of Medicinal Chemistry*, **2009**, 52, 4020-5	8.3	4
73	Searching for new NO-donor aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid. *Journal of Medicinal Chemistry*, **2008**, 51, 1894-903	8.3	34
72	Multitarget drugs: Focus on the NO-donor hybrid drugs. *Pure and Applied Chemistry*, **2008**, 80, 1693-1701	2.1	17
71	A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages. *Journal of Inflammation*, **2008**, 5, 12	6.7	27
70	Structure-antioxidant activity relationships in a series of NO-donor phenols. *ChemMedChem*, **2008**, 3, 1443-8	3.7	4
69	Physicochemical Profiling of Sartans: A Detailed Study of Ionization Constants and Distribution Coefficients. *Helvetica Chimica Acta*, **2008**, 91, 468-482	2	43
68	Novel antioxidant agents deriving from molecular combination of Vitamin C and NO-donor moieties. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 5199-206	3.4	15
67	NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. *Journal of Medicinal Chemistry*, **2007**, 50, 1449-57	8.3	52
66	Amphiphilic NO-donor antioxidants. *ChemMedChem*, **2007**, 2, 234-40	3.7	2
65	NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization. *Journal of Pineal Research*, **2007**, 42, 371-85	10.4	12
64	Nitric oxide donor beta2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans. *Journal of Medicinal Chemistry*, **2007**, 50, 5003-11	8.3	22

63	Synthesis, chiral HPLC resolution and configuration assignment of 1-phenylglyceryl trinitrate stereomers. *Chirality*, **2006**, 18, 430-6	2.1	6
62	The Lipophilicity Behavior of Three Catechol-O-methyltransferase (COMT) Inhibitors and Simple Analogues. *Helvetica Chimica Acta*, **2006**, 89, 144-152	2	11
61	Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of gamma-aminobutyric acid (GABA) related compounds. *Journal of Medicinal Chemistry*, **2006**, 49, 4442-6	8.3	26
60	Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets. *British Journal of Pharmacology*, **2006**, 148, 517-26	8.6	48
59	NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties. *Journal of Medicinal Chemistry*, **2006**, 49, 2886-97	8.3	43
58	Synthesis of NO-donor bisphosphonates and their in-vitro action on bone resorption. *Journal of Medicinal Chemistry*, **2005**, 48, 1322-9	8.3	22
57	The relationship between redox potentials and substituent constants in biologically active arylazoxy compounds. *Journal of Electroanalytical Chemistry*, **2005**, 579, 33-41	4.1	4
56	Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 4750-9	3.4	13
55	Non-imidazole histamine NO-donor H3-antagonists. *Il Farmaco*, **2005**, 60, 507-12		5
54	The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities. *Chemistry and Biodiversity*, **2005**, 2, 886-900	2.5	28
53	NO donors: Focus on furoxan derivatives. *Pure and Applied Chemistry*, **2004**, 76, 973-981	2.1	55
52	A new class of NO-donor H3-antagonists. *Il Farmaco*, **2004**, 59, 359-71		11
51	New 1,4-dihydropyridines endowed with NO-donor and calcium channel agonist properties. *Journal of Medicinal Chemistry*, **2004**, 47, 2688-93	8.3	38
50	Liposome/water lipophilicity: methods, information content, and pharmaceutical applications. *Medicinal Research Reviews*, **2004**, 24, 299-324	14.4	86
49	Evidence of self-protonation on the electrodic reduction mechanism of an anti-Helicobacter pylori metronidazole isotere. *Journal of Electroanalytical Chemistry*, **2004**, 571, 177-182	4.1	8
48	Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5971-4	2.9	23
47	Synthesis and vasodilating properties of N-alkylamide derivatives of 4-amino-3-furoxancarboxylic acid and related azo derivatives. *Il Farmaco*, **2003**, 58, 677-81		16
46	Synthesis and anti-Helicobacter pylori properties of NO-donor/metronidazole hybrids and related compounds. *Drug Development Research*, **2003**, 60, 225-239	5.1	27

45	A new furoxan NO-donor rabeprazole derivative and related compounds. *ChemBioChem*, **2003**, 4, 899-903	3.8	18
44	Electrochemical studies of biologically active arylazoxy compounds. The relationship between redox potentials and molluscicidal activities. *Journal of Electroanalytical Chemistry*, **2003**, 544, 25-34	4.1	11
43	[3-(1H-imidazol-4-yl)propyl]guanidines containing furoxan moieties: a new class of H3-antagonists endowed with NO-donor properties. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 1197-205	3.4	21
42	New potential uroselective NO-donor alpha1-antagonists. *Journal of Medicinal Chemistry*, **2003**, 46, 376285	8.3	14
41	Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. *Journal of Medicinal Chemistry*, **2003**, 46, 747-54	8.3	84
40	Platelet antiaggregatory effects and haemodynamic activity of two terfuroxan isomer pairs. *Il Farmaco*, **2002**, 57, 417-20		4
39	Michael addition of Grignard reagents to tetraethyl ethenylidenebisphosphonate. *Journal of Organometallic Chemistry*, **2002**, 650, 77-83	2.3	24
38	Molecular factors influencing retention on immobilized artifical membranes (IAM) compared to partitioning in liposomes and n-octanol. *Pharmaceutical Research*, **2002**, 19, 729-37	4.5	74
37	Thermolysis of 4-(2-azido-3-nitrophenyl)-1,4-dihydropyridines as source of Ɛ-carboline derivatives and some related compounds. *Tetrahedron Letters*, **2001**, 42, 4507-4510	2	2
36	Molecular-Dynamics and NMR Investigation of the Property Space of the Zwitterionic Antihistamine Cetirizine. *Helvetica Chimica Acta*, **2001**, 84, 360-374	2	9
35	Ionic Partition Diagram of the Zwitterionic Antihistamine Cetirizine. *Helvetica Chimica Acta*, **2001**, 84, 375-387	2	27
34	A new class of ibuprofen derivatives with reduced gastrotoxicity. *Journal of Medicinal Chemistry*, **2001**, 44, 3463-8	8.3	63
33	Searching for balanced hybrid NO-donor 1,4-dihydropyridines with basic properties. *Pharmaceutical Research*, **2001**, 18, 987-91	4.5	13
32	Lipophilicity behaviour of the Zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. *Pharmaceutical Research*, **2001**, 18, 694-701	4.5	35
31	Studies on agents with mixed NO-dependent and calcium channel antagonistic vasodilating activities. *Pharmaceutical Research*, **2001**, 18, 157-65	4.5	15
30	Nitroanilines are the reduction products of benzofuroxan system by oxyhemoglobin (HbO2 2+). *Il Farmaco*, **2001**, 56, 799-802		9
29	Unsymmetrically substituted furoxans. Part 18. Smiles rearrangement in furoxan systems and in related furazans. *Journal of the Chemical Society, Perkin Transactions 1*, **2001**, 1751-1757		23
28	Nicorandil analogues containing NO-donor furoxans and related furazans. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 1727-32	3.4	11

27	Synthesis of new bicyclic analogues of glutamic acid. *Tetrahedron*, **1999**, 55, 5623-5634	2.4	21
26	NO donor and biological properties of different benzofuroxans. *Pharmaceutical Research*, **1999**, 16, 956-60	4.5	43
25	Structure-Property Relationships in the Basicity and Lipophilicity of Arylalkylamine Oxides. *Helvetica Chimica Acta*, **1999**, 82, 1630-1639	2	7
24	Synthesis and voltage-clamp studies of methyl 1,4-dihydro-2, 6-dimethyl-5-nitro-4-(benzofurazanyl)pyridine-3-carboxylate racemates and enantiomers and of their benzofuroxanyl analogues. *Journal of Medicinal Chemistry*, **1999**, 42, 1422-7	8.3	34
23	Mechanisms of liposomes/water partitioning of (p-methylbenzyl)alkylamines. *Pharmaceutical Research*, **1998**, 15, 1407-13	4.5	36
22	Electronic Substituent Effects of Furoxan and Furazan Systems. *Journal of Chemical Research Synopses*, **1998**, 495-495		2
21	Water soluble furoxan derivatives as NO prodrugs. *Journal of Medicinal Chemistry*, **1997**, 40, 463-9	8.3	87
20	Inhibition of human placenta glutathione transferase P1-1 by the antibiotic calvatic acid and its diazocyanide analogue--evidence for multiple catalytic intermediates. *FEBS Journal*, **1997**, 245, 663-7		7
19	Studies on agents with mixed NO-dependent vasodilating and beta-blocking activities. *Pharmaceutical Research*, **1997**, 14, 1750-8	4.5	24
18	Unsymmetrically substituted furoxans. Part 16 . Reaction of benzenesulfonyl substituted furoxans with ethanol and ethanethiol in basic medium. *Journal of Heterocyclic Chemistry*, **1996**, 33, 327-334	1.9	38
17	The furoxan system as a useful tool for balancing "hybrids" with mixed alpha 1-antagonist and NO-like vasodilator activities. *Journal of Medicinal Chemistry*, **1995**, 38, 4944-9	8.3	36
16	Alpha 1-adrenoceptor blocking activity of some ring-open analogues of prazosin. *Archiv Der Pharmazie*, **1994**, 327, 661-7	4.3	13
15	Dipole moments and electron distribution of furoxans and furazans. *Journal of Molecular Structure*, **1994**, 324, 277-282	3.4	10
14	Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: thiol-mediated nitric oxide release and biological evaluation. *Journal of Medicinal Chemistry*, **1994**, 37, 4412-6	8.3	107
13	Unsymmetrically Substituted Furoxans, XIV. Synthesis and Structure of a Trimer of the Furoxan System with High Vasodilator and Platelet Antiaggregatory Activity. *Liebigs Annalen Der Chemie*, **1993**, 1993, 441-444		16
12	Inhibition of human alpha-, beta- and gamma-thrombin by mono-, bis-, tris- and tetra-benzamidine structures: thermodynamic study. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1992**, 6, 131-9		5
11	Characterization of a new compound, S35b, as a guanylate cyclase activator in human platelets. *Biochemical Pharmacology*, **1992**, 43, 1281-8	6	38
10	Reversed-phase high-performance liquid chromatographic study of the lipophilicity of a series of analogues of the antibiotic calvatic acid *Journal of Chromatography A*, **1991**, 547, 167-173	4.5	9

9	Unsymmetrically substituted furoxans, XIII. Phenylfuroxancarbaldehydes and related compounds. *Liebigs Annalen Der Chemie*, **1991**, 1991, 1211-1213		26
8	Mesomeric dipole moments. Part 12. *Structural Chemistry*, **1990**, 1, 417-421	1.8	11
7	Unsymmetrically substituted furoxans, XII. Phenylfuroxancarboxylic acids and their derivatives. *Liebigs Annalen Der Chemie*, **1990**, 1990, 335-338		18
6	Electronic and Hydrophobic Constants of Azoxy Groups Containing Electron Withdrawing Functions. *QSAR and Combinatorial Science*, **1988**, 7, 26-30		5
5	13 C and 15N solution and solid-state nuclear magnetic resonance study of the intermolecular interactions in the 1 : 1 trimethoprim sulphamethoxazole complex. *Journal of the Chemical Society Perkin Transactions II*, **1988**, 1863		6
4	Oximation of acetyl(hydroxyimino)acetone: nuclear magnetic resonance spectroscopic, chemical, and X-ray crystallographic studies of the reaction products. *Journal of the Chemical Society Perkin Transactions II*, **1987**, 523		12
3	Acyclic analogs of classical H2-antagonists: synthesis and activity of dialkylamioalkyl substituted ethers and oximes. *European Journal of Medicinal Chemistry*, **1987**, 22, 255-259	6.8	6
2	Chemical and biological studies on calvatic acid and its analogs. *Journal of Antibiotics*, **1986**, 39, 864-8	3.7	19
1	A directed synthesis of alkyl, aryl, and heteroaryl-ONN-azoxycyanides. *Journal of the Chemical Society Chemical Communications*, **1984**, 323		13